by Stacey Johnson | Jan 31, 2025
In a new location, with highways replacing waterways, it’s comforting to have an agenda with some consistent touchpoints for familiarity, and Advanced Therapies Week 2025 (ATW25), January 20-23 in Dallas, Texas, began with two of my favourites: the Super plenary,...
by Stacey Johnson | Nov 29, 2024
Are you familiar with the Gartner Hype Cycle? It’s a way of separating reality from hype when it comes to emerging technologies – like cell and gene therapies (CGTs). The hype cycle employs a graph to present the maturity of new technologies as they pass through five...
by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Stacey Johnson | Jun 28, 2024
As June comes to an end, so does Pride Month in Canada. In 12 years of blogging for Signals, I realize I have never covered the topic of STEM (science, technology, engineering and mathematics) and Pride, although I have written about Equity, Diversity and Inclusion...
by Stacey Johnson | Mar 29, 2024
Dr. Michel Sadelain, the “inventor of T cells” and a graduate of the University of Alberta, has won the 2024 Breakthrough Prize in life sciences. After completing his medical degree at the University of Paris, Dr. Sadelain earned his PhD in immunology at the...
Comments